Talk:Ultragenyx

This article was nominated for deletion review on Christmas 2020. The result of the discussion was restored.

notability issues ? reads like an ad ?

please elaborate. at $12 billion USD market cap this is possibly the largest biopharmaceutical company without an article. Company founder and CEO Emil Kakkis is notable only because of the accomplishments of Ultragenyx. the company's gene therapy technology is being used by Daiichi Sankyo to manufacture investigational drugs for AAV gene therapy. journal citations mentioning the company are numerous and easy to find. most of the company's growth and products were/are being developed within the last year. a number of the most important ones are still in the trial phase for FDA approval. more than 20 articles on gene therapy/bio pharmaceuticals are directly associated with the company. many more articles discuss its products. notability should not even be a question.Grmike (talk) 09:34, 24 December 2020 (UTC)grmike[reply]

reads like an ad ? help me correct this. Before contributing to the article I read a number of wikipedia's articles on pharmaceutical companies. IMO the tone of this article is no different from those.Grmike (talk) 09:34, 24 December 2020 (UTC)grmike[reply]

I see that they've had negative results as well as positive. Maybe include some mention of these if you want to conform to the NPOV guideline. Deb (talk) 18:51, 24 December 2020 (UTC)[reply]

Contested deletion

This page is not unambiguously promotional, because it talks about the company in a positive and negative context. It includes citations from journal publications. because it is self evident. What more can I say ? The article had already been reviewed. --Grmike (talk) 00:58, 27 December 2020 (UTC)grmike[reply]

the previous deleting administrator undeleted the article the following day. It was also listed at the AFD review for December 25, where it received support.Grmike (talk) 01:47, 27 December 2020 (UTC)grmike[reply]

if there is any other user out there who disagrees with the speedy delete tag please remove it as I as the creator or the article am not allowed to.Grmike (talk) 01:49, 27 December 2020 (UTC)grmike[reply]

I have removed the speedy tag. It was already restored after a speedy. The db-spam tagging is incorrect since it is not unambiguously promotional (though could definitely be rewritten to be better!). Given size of company, sources such as reference 3 already present, and the analyst coverage reported at the company's investor relations page, this company does in my opinion also pass the notability test -- a discussion which may occur at AFD if someone wants to have it. See also Wikipedia:Deletion_review/Log/2020_December_25#Ultragenyx Martinp (talk) 02:09, 27 December 2020 (UTC)[reply]

Sourcing

The main problem seems to be that all medical content must comply with WP:MEDRS in its sourcing. This rules out not only the use of press releases, company material and news coverage, but also all primary research papers. The only sourcing that is permitted for medical claims is independent reviews in reliable journals or books. It is usually also considered acceptable to note that drugs have been approved by FDA/EMA &c for indication xyz, referencing the relevant announcement. Espresso Addict (talk) 02:27, 27 December 2020 (UTC)[reply]

Does this rule out studies done by other companies ? or perhaps only when Ultragenyx is involved.Grmike (talk) 02:46, 28 December 2020 (UTC)grmike[reply]